| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total revenue | 20,750 | 15,288 | 14,108 | |
| Research and development | 67,908 | 62,785 | 55,973 | |
| General and administrative | 32,839 | 25,169 | 22,835 | |
| Total operating expenses | 100,747 | 87,954 | 78,808 | |
| Loss from operations | -79,997 | -72,666 | -64,700 | |
| Interest and other income | 6,274 | 6,935 | 7,879 | |
| Interest expense | 393 | 391 | 382 | |
| Total other income, net | 5,881 | 6,544 | 7,497 | |
| Loss before income taxes | -74,116 | -66,122 | -57,203 | |
| Income tax expense | - | - | 226 | |
| Net loss | -74,116 | -66,122 | -57,429 | |
| Earnings per share, basic, total | -0.85 | -0.75 | -0.66 | |
| Earnings per share, diluted, total | -0.85 | -0.75 | -0.66 | |
| Weighted average number of shares outstanding, basic, total | 87,645,000 | 87,586,000 | 87,415,000 | |
| Weighted average number of shares outstanding, diluted, total | 87,645,000 | 87,586,000 | 87,415,000 | |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)